Detailed explanation of the efficacy and functions of obeticholic acid tablets

Obeticholic acid is a new type of drug mainly used to treat primary biliary cirrhosis (PBC). The disease is an autoimmune disorder that causes progressive damage to the bile ducts and liver, leading to fibrosis and cirrhosis. In this case, the accumulation of bile acids increases the risk of bile duct damage and liver fibrosis.

Obeeticholic acid is a farnesoidX receptor (FXR) agonist. Its mechanism of action is to regulate bile and cholesterol metabolism by binding to FXR located in the nucleus of liver and intestinal cells. After activating FXR, obeticholic acid can increase hepatic bile flow while inhibiting bile synthesis, reducing the risk of hepatocytes being exposed to excess bile acids. Cholestasis is often a key factor in inflammation and cirrhosis, and obeticholic acid can effectively reduce these adverse effects by reducing bile acid synthesis.

Through its FXR agonist properties, obeticholic acid not only reduces bile acid synthesis but also inhibits biomarkers associated with inflammation, thereby attenuating the progression of liver fibrosis. Existing research shows that obeticholic acid may improve the survival rate of PBC patients. However, the direct relationship between cholic acid and survival rate is still not fully understood.

In clinical application, obeticholic acid is usually combined with ursodeoxycholic acid (UDCA) and is suitable for PBC patients who have insufficient response to UDCA or cannot tolerate UDCA. This combination drug strategy aims to enhance treatment efficacy and improve patients' quality of life.

In general, obeticholic acid, as aFXR agonist, has shown positive effects in improving bile acid metabolism and reducing liver damage, making it one of the important choices for the treatment of PBC. With further research on its mechanism of action, obeticholic acid will have broader application prospects and is expected to bring new treatment options to more patients with liver diseases.

Reference materials:https://go.drugbank.com/drugs/DB05990